Pharma
Support for psychedelic treatments means full steam ahead at Compass, despite stock drop
Investors were seemingly not satisfied with psilocybin trial results, but the psychedelic health community disagrees.
Karen Fischer
Karen Fischer is an independent writer and reporter. You can find some of her bylines at The Verge, Eater, and CQ Researcher, as well as on her website, kfischerwrites.com. She also produces The Gumbo Pot, a weekly Substack of independent reportage on education, health, culture, infrastructure, food, and energy.